Social Media Ideas for Sponsored-Lynparza

Eli Lilly releases promising early-stage data on ADC for ovarian cancer

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congres...

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRО±-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentation

Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial

Dealing With A Breast Cancer Diagnosis? Here’s Where To Start

The more you know, the better prepared you’ll feel.

Dealing With A Breast Cancer Diagnosis? Here’s Where To Start

The more you know, the better prepared you’ll feel.

<![CDATA[FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer]]>

<![CDATA[Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboa...

<![CDATA[FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer]]>

<![CDATA[Merck Licenses Preclinical KRAS G12D Inhibitor from SciBrunch]]>

AstraZeneca’s newly approved pill fails frontline breast cancer study

Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year. 

Merck, Daiichi end plans to seek speedy approval of lung cancer ADC

The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving...

<![CDATA[Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli]]>

BRCA mutation status in breast cancer: My approach to timing, testing and treatment

This article is sponsored by AstraZeneca. As a medical professional and oncologist, personalized and compassionate care has been a core pillar of my approach. I learned early in my...

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Nega...

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II...

Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture...

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success

<![CDATA[Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Cl...

Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication f...

INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication...

<![CDATA[Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Ente...

Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal

New follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.

Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue

Merck agreed to pay SciBrunch up to $2.13 billion consisting of $400 million upfront and the remainder in payments tied to achieving milestones across multiple indications. The pos...

FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer

From: .onclive.com The FDA has granted fast track designation to ETX-19477 for the treatment of adult patients with BRCA-mutated, hormone receptor (HR)–positive, HER2-negative unre...

Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch

Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the cancer-driving protein KRAS G12D. This class of targeted cancer the...

Akeso, Summit cancer drug confirms lung cancer survival benefit

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.